Veracyte Inc (NASDAQ:VCYT) — Market Cap & Net Worth
Market Cap & Net Worth: Veracyte Inc (VCYT)
Veracyte Inc (NASDAQ:VCYT) has a market capitalization of $2.83 Billion ($2.83 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5007 globally and #1686 in its home market, demonstrating a -19.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Veracyte Inc's stock price $46.32 by its total outstanding shares 79049173 (79.05 Million). See Veracyte Inc (VCYT) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Veracyte Inc Market Cap History: 2015 to 2026
Veracyte Inc's market capitalization history from 2015 to 2026. Data shows growth from $569.15 Million to $3.66 Billion (20.07% CAGR).
Index Memberships
Veracyte Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$935.64 Billion | 0.30% | #27 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.11% | #126 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #571 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.16% | #79 of 263 |
Weight: Veracyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Veracyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Veracyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.02x
Veracyte Inc's market cap is 7.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
129.69x
Veracyte Inc's market cap is 129.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $569.15 Million | $49.50 Million | -$33.70 Million | 11.50x | N/A |
| 2016 | $611.84 Million | $65.08 Million | -$31.36 Million | 9.40x | N/A |
| 2017 | $516.19 Million | $71.95 Million | -$31.00 Million | 7.17x | N/A |
| 2018 | $994.44 Million | $92.01 Million | -$23.00 Million | 10.81x | N/A |
| 2019 | $2.21 Billion | $120.37 Million | -$12.60 Million | 18.34x | N/A |
| 2020 | $3.87 Billion | $117.48 Million | -$34.91 Million | 32.93x | N/A |
| 2021 | $3.26 Billion | $219.51 Million | -$75.56 Million | 14.84x | N/A |
| 2022 | $1.88 Billion | $296.54 Million | -$36.56 Million | 6.33x | N/A |
| 2023 | $2.17 Billion | $361.05 Million | -$74.40 Million | 6.02x | N/A |
| 2024 | $3.13 Billion | $445.76 Million | $24.14 Million | 7.02x | 129.69x |
Competitor Companies of VCYT by Market Capitalization
Companies near Veracyte Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Veracyte Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.77 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #169 globally with a market cap of $137.72 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.48 Billion USD ( CN¥317.64 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #616 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.77 Billion | $574.30 |
| #169 | Danaher Corporation | NYSE:DHR | $137.72 Billion | $194.98 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.48 Billion | CN¥128.43 |
| #616 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $559.07 |
Veracyte Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Veracyte Inc's market cap moved from $569.15 Million to $ 3.66 Billion, with a yearly change of 20.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.66 Billion | +10.02% |
| 2025 | $3.33 Billion | +6.31% |
| 2024 | $3.13 Billion | +43.95% |
| 2023 | $2.17 Billion | +15.93% |
| 2022 | $1.88 Billion | -42.40% |
| 2021 | $3.26 Billion | -15.82% |
| 2020 | $3.87 Billion | +75.29% |
| 2019 | $2.21 Billion | +121.94% |
| 2018 | $994.44 Million | +92.65% |
| 2017 | $516.19 Million | -15.63% |
| 2016 | $611.84 Million | +7.50% |
| 2015 | $569.15 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Veracyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.83 Billion USD |
| MoneyControl | $2.83 Billion USD |
| MarketWatch | $2.83 Billion USD |
| marketcap.company | $2.83 Billion USD |
| Reuters | $2.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more